A systematic review on the correlation between COVID-19 and lower urinary tract symptoms

IF 1.4 Q4 INFECTIOUS DISEASES Journal of clinical virology plus Pub Date : 2025-02-01 Epub Date: 2025-01-04 DOI:10.1016/j.jcvp.2025.100202
Ashkan Shafigh , Amir Mohammadi-Garebagh , Kavous Shahsavarinia , Sona Tayebi , Ali Mostafaei , Hanieh Salehi-Pourmehr , Sakineh Hajebrahimi
{"title":"A systematic review on the correlation between COVID-19 and lower urinary tract symptoms","authors":"Ashkan Shafigh ,&nbsp;Amir Mohammadi-Garebagh ,&nbsp;Kavous Shahsavarinia ,&nbsp;Sona Tayebi ,&nbsp;Ali Mostafaei ,&nbsp;Hanieh Salehi-Pourmehr ,&nbsp;Sakineh Hajebrahimi","doi":"10.1016/j.jcvp.2025.100202","DOIUrl":null,"url":null,"abstract":"<div><div>COVID-19 can lead to extrapulmonary symptoms such as Lower Urinary Tract Symptoms (LUTS). We aimed to investigate the impact of the severity of SARS-CoV-2 infection on the lower urinary tract in patients affected by COVID-19. We conducted a comprehensive literature search using the terms \"COVID-19,\" \"SARS-CoV-2,\" and \"Lower Urinary Tract Symptoms\" with various combinations in MEDLINE, Scopus, ProQuest, Web of Science, Google Scholar, and Cochrane Library, including Cochrane Central Register of Controlled Trials (CENTRAL) and Cochrane Database of Systematic Reviews (CDSR) databases. The studies were selected based on eligibility criteria, and quantitative data were extracted using the data extraction tool from JBI-MAStARI. A total of 988 articles were found through the literature search. Twenty-five articles were included in our qualitative evaluation, and seven studies were included in the quantitative analysis. The qualitative publications were systematically reviewed separately under the titles of LUTS, benign prostatic hyperplasia (BPH), and kidney failures or kidney transplant recipients. The analysis of eligible studies showed a 3.3 % prevalence of LUTS in infected patients (95 % CI: 2.0 % - 5.3 %; Q-value: 1021.397, I2: 97.45 %). Furthermore, frequency and urgency were the most prevalent symptoms in the eligible meta-analysis studies, with 15.3 % (95 % CI: 5.7 % – 34.9 % in 4 studies) and 11.5 % (95 % CI: 7.1 % - 18.1 % in two studies), respectively. The prevalence of LUTS among COVID-19 patients was 3.3 %, with common symptoms including urinary frequency, urgency, UTI, and hematuria. Long-term follow-up and consideration of pre-existing LUTS are essential for improving understanding and clinical management.</div></div>","PeriodicalId":73673,"journal":{"name":"Journal of clinical virology plus","volume":"5 1","pages":"Article 100202"},"PeriodicalIF":1.4000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of clinical virology plus","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667038025000018","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/4 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"INFECTIOUS DISEASES","Score":null,"Total":0}
引用次数: 0

Abstract

COVID-19 can lead to extrapulmonary symptoms such as Lower Urinary Tract Symptoms (LUTS). We aimed to investigate the impact of the severity of SARS-CoV-2 infection on the lower urinary tract in patients affected by COVID-19. We conducted a comprehensive literature search using the terms "COVID-19," "SARS-CoV-2," and "Lower Urinary Tract Symptoms" with various combinations in MEDLINE, Scopus, ProQuest, Web of Science, Google Scholar, and Cochrane Library, including Cochrane Central Register of Controlled Trials (CENTRAL) and Cochrane Database of Systematic Reviews (CDSR) databases. The studies were selected based on eligibility criteria, and quantitative data were extracted using the data extraction tool from JBI-MAStARI. A total of 988 articles were found through the literature search. Twenty-five articles were included in our qualitative evaluation, and seven studies were included in the quantitative analysis. The qualitative publications were systematically reviewed separately under the titles of LUTS, benign prostatic hyperplasia (BPH), and kidney failures or kidney transplant recipients. The analysis of eligible studies showed a 3.3 % prevalence of LUTS in infected patients (95 % CI: 2.0 % - 5.3 %; Q-value: 1021.397, I2: 97.45 %). Furthermore, frequency and urgency were the most prevalent symptoms in the eligible meta-analysis studies, with 15.3 % (95 % CI: 5.7 % – 34.9 % in 4 studies) and 11.5 % (95 % CI: 7.1 % - 18.1 % in two studies), respectively. The prevalence of LUTS among COVID-19 patients was 3.3 %, with common symptoms including urinary frequency, urgency, UTI, and hematuria. Long-term follow-up and consideration of pre-existing LUTS are essential for improving understanding and clinical management.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19与下尿路症状相关性的系统综述
COVID-19可导致肺外症状,如下尿路症状(LUTS)。我们旨在探讨SARS-CoV-2感染严重程度对COVID-19患者下尿路的影响。我们在MEDLINE、Scopus、ProQuest、Web of Science、谷歌Scholar和Cochrane图书馆(包括Cochrane中央对照试验注册库(Central)和Cochrane系统评价数据库(CDSR)数据库中使用“COVID-19”、“SARS-CoV-2”和“下尿路症状”等不同组合进行了全面的文献检索。根据入选标准选择研究,并使用JBI-MAStARI的数据提取工具提取定量数据。通过文献检索共找到988篇文章。我们的定性评价纳入了25篇文章,定量分析纳入了7篇研究。定性出版物分别在LUTS,良性前列腺增生(BPH)和肾衰竭或肾移植受者的标题下进行系统审查。对符合条件的研究的分析显示,感染患者中LUTS的患病率为3.3% (95% CI: 2.0% - 5.3%;q值:1021.397,I2: 97.45%)。此外,在符合条件的meta分析研究中,频率和急迫性是最常见的症状,分别为15.3%(4项研究中95% CI: 5.7% - 34.9%)和11.5%(2项研究中95% CI: 7.1% - 18.1%)。COVID-19患者中LUTS的患病率为3.3%,常见症状包括尿频、尿急、尿路感染和血尿。长期随访和考虑预先存在的LUTS是提高认识和临床管理的必要条件。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of clinical virology plus
Journal of clinical virology plus Infectious Diseases
CiteScore
2.20
自引率
0.00%
发文量
0
审稿时长
66 days
期刊最新文献
Interest and performances of HIV whole genome next‐generation sequencing in a diagnosis laboratory Molecular detection of human herpesviruses in pleural effusions after lung transplantion Liver involvement in dengue virus infection: a narrative review Hepatitis B and C virus infections promote hepatic fibrosis in HIV/AIDS patients in Jiangxi, China Siemens Healthineers cross-platform verification: Analytical and clinical analysis of HIV Antigen/Antibody Combo assay across ADVIA Centaur and Atellica analyzers
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1